Skip to content
Homepage
Category:
Trending
Posted Date:
June 5, 2026
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Bluejay Diagnostics, Inc.
June 5, 2026
Global Aerospace’s SM4 Aviation Safety Program Offers Essentials on Sleep Need vs. Sleep Capacity and The Science of Sleep Banking
Global Aerospace
June 5, 2026
Tidepool Showcases New Real-World Clinical Data and Landmark Women’s Health Initiative at ADA 2026
Business Wire
June 5, 2026
CueCue Launches Interactive Web Card to Help People Earn From Skills, Services and Idle Assets
PR Underground
June 5, 2026
All-Round for Work & Play: KTC Dual-Mode Monitor H27P6 Adapts to Full-Scenario Needs
KTC TECHNOLOGY (HONGKONG) CO., LIMITED
June 5, 2026
Why you need independent energy this summer and beyond
Edgenewswire
June 5, 2026
NatureU® Now Has Three Clinical Studies Publicly Registered on ClinicalTrials.gov as 56-Day PQQ Skin-Aging Study (NCT07571629) Joins Two Previously Published Peer-Reviewed Trials
NatureU®
June 5, 2026
Fragrance Creators Association Makes History at the White House, Advancing the $80 Billion Case for Responsible Innovation to Senior Executive Branch Officials
Fragrance Creators Association
June 5, 2026
Procore and OneNotary Bring Credentialed Notarization Directly Into Construction Payments
Written By: EIN Presswire
June 5, 2026
Pahrump Brothel Adds Bitcoin and Ethereum Payment Options
PR Quantum
June 5, 2026
AI Straight Talk on TV Show from ‘Hands-On-Keyboard’ Engineer
Written By: EIN Presswire
June 5, 2026
Aqualia refuerza su liderazgo en innovación hídrica durante la IWA Leading Edge Conference 2026 en Houston
Written By: EIN Presswire
June 5, 2026
Coming Soon: Dr. Angel A. Diaz’s New Book Explains the Hidden War for Innovation, Security, and Power
Written By: EIN Presswire
June 5, 2026
Hyperbaric Chamber Nashville: How HBOT, IV Therapy, and EBO2 Support Personalized Recovery Protocols
Written By: EIN Presswire
June 5, 2026
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
Kailera Therapeutics, Inc.
June 5, 2026
Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026
NOVO NORDISK INC.
June 5, 2026
Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate
Ambrosia Biosciences
June 5, 2026
Prev
1
…
1,001
1,002
1,003
